ImmunityBio IBRX
NASDAQ IBRX
$8.64 -0.13 (-1.48%)
At close: Oct 21, 2026 · 4:00 PM EDT

ImmunityBio (IBRX) Equity Income (2021 - 2023)

Updated

ImmunityBio's Equity Income came in at -$7.55 million for FY2023, compared with -$12.11 million in FY2022.

Analysis

ImmunityBio (IBRX) Equity Income (2021 - 2023) Analysis & Trends

  • Per Business Quant, earlier years put Equity Income at -$12.11 million in FY2022 and -$803,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -2.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -10.00 Mn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 ImmunityBio 9.07 Bn 7.83 Bn 50.94 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 -1.26 Mn
Jun 30, 2023 -3.96 Mn
Mar 31, 2023 -2.34 Mn
Dec 31, 2022 -3.55 Mn
Sep 30, 2022 -4.46 Mn
Jun 30, 2022 -3.90 Mn
Mar 31, 2022 -197,000.00
Dec 31, 2021 -803,000.00
API Access

ImmunityBio Equity Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=equity-income&ticker=IBRX&period=max&api_key=YOUR_API_KEY